




# Medicare & Medicaid Coverage of GLP-1 Agonists for Treatment of Obesity

2023 COVERAGE OF GLP-1 AGONISTS FOR CHRONIC WEIGHT MANAGEMENT BY STATE MEDICAID PROGRAM



■ No Coverage    ■ Covered    ■ Future Coverage

Medicaid utilization of GLP-1 agonists is likely to increase as new GLP-1 agonists are approved and existing therapies gain approval for expanded indications.

Studies are underway for additional GLP-1 agonists

GLP-1 agonists approved by the FDA are also being investigated for a variety of expanded indications, including Alzheimer's disease, heart failure, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease.

Oral formulations are also being studied

\*Illinois plans to review the class for drug placement based on a recent recommendation from the Drugs and Therapeutic Advisory Board.

†Connecticut's coverage is pending recently passed legislation

Adapted from Niakan K, et al. GLP-1 agonists in Medicaid: Utilization, growth, and management. *Milliman White Paper*. 2024